{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:05:26Z","timestamp":1791925526475,"version":"4.3.4"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Complement-dependent cytotoxicity (CDC) results from cell lysis induced by the membrane attack complex (MAC), a pore-forming structure assembled at the terminal stage of the complement cascade that disrupts membrane integrity and causes osmotic cell death. Several methodological approaches are available to assess CDC efficacy\n                    <jats:italic>in vitro<\/jats:italic>\n                    , including (i) dye influx assays that report complement-mediated membrane permeabilization (e.g., propidium iodide staining), (ii) dye-release assays using preloaded fluorescent probes (e.g., calcein-AM), and (iii) assays based on cellular metabolic activity (e.g., MTT, XTT, or Alamar Blue) or ATP content (e.g., CellTiter-Glo). Because complement acts rapidly, often killing target cells within seconds to minutes, and because some staining procedures are cytotoxic or require time-consuming steps that may introduce artefacts, selecting an appropriate, high-throughput assay is not trivial. In this study, we evaluated representative methods from each assay class (dye influx, dye release, and metabolic readouts) to measure CDC triggered by the therapeutic anti-CD20 antibody rituximab in two human lymphoma cell lines expressing the CD20 antigen. Based on our findings, we discuss the strengths and limitations of each approach, with particular emphasis on their susceptibility to false-positive and false-negative results.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1786368","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:28:54Z","timestamp":1773293334000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Selection of laboratory assays for reliable assessment of complement-dependent cytotoxicity: impact of assay choice on CDC quantification"],"prefix":"10.3389","volume":"17","author":[{"given":"Alan","family":"Majeranowski","sequence":"first","affiliation":[{"name":"Intercollegiate Faculty of Biotechnology, University of Gda\u0144sk and Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Stasi\u0142oj\u0107","sequence":"additional","affiliation":[{"name":"Intercollegiate Faculty of Biotechnology, University of Gda\u0144sk and Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Panasiuk","sequence":"additional","affiliation":[{"name":"Intercollegiate Faculty of Biotechnology, University of Gda\u0144sk and Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Okr\u00f3j","sequence":"additional","affiliation":[{"name":"Intercollegiate Faculty of Biotechnology, University of Gda\u0144sk and Medical University of Gda\u0144sk","place":["Gda\u0144sk, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02114","article-title":"100th anniversary of Jules Bordet\u2019s Nobel Prize: Tribute to a founding father of immunology","volume":"10","author":"Cavaillon","year":"2019","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/S0140-6736(23)01524-6","article-title":"Complement in human disease: Approved and up-and-coming therapeutics","volume":"403","author":"West","year":"2024","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00262","article-title":"Complement system part I - Molecular mechanisms of activation and regulation","volume":"6","author":"Merle","year":"2015","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ctrv.2016.02.009","article-title":"New perspectives on complement mediated immunotherapy","volume":"45","author":"Stasi\u0142oj\u0107","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2024.101921","article-title":"The complement system in clinical oncology: Applications, limitations and challenges","volume":"77","author":"Ajona","year":"2024","journal-title":"Semin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/tan.15010","article-title":"C3d-binding assay for the detection of complement activating HLA antibodies: A useful tool for allocation to highly sensitised recipients in the post-CDC era","volume":"102","author":"Wong","year":"2023","journal-title":"HLA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2022.02.001","article-title":"Reducing number of laboratories performing complement dependent cytotoxicity crossmatching: Reasons and conclusions","volume":"83","author":"Putheti","year":"2022","journal-title":"Hum Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584509","article-title":"Monitoring of the complement system status in patients with B-cell Malignancies treated with rituximab","volume":"11","author":"Felberg","year":"2020","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.146","article-title":"Complement deficiencies limit CD20 monoclonal antibody treatment efficacy in CLL","volume":"29","author":"Middleton","year":"2015","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1600648","article-title":"Antibodies that efficiently form hexamers upon antigen binding can induce complement-dependent cytotoxicity under complement-limiting conditions","volume":"197","author":"Cook","year":"2016","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12388","article-title":"A novel method for direct measurement of complement convertases activity in human serum","volume":"178","author":"Blom","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0759-5","article-title":"Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement","volume":"30","author":"Okroj","year":"2013","journal-title":"Med Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16010049","article-title":"The acquisition of complement-dependent cytotoxicity by the type II anti-CD20 therapeutic antibody obinutuzumab","volume":"16","author":"Ku\u017aniewska","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.04.058","article-title":"A cell-based assay to measure the activity of the complement convertases","volume":"9","author":"Stasi\u0142oj\u0107","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.124388","article-title":"The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation","volume":"126","author":"Triantafilou","year":"2013","journal-title":"J Cell Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1182\/blood-2019-128704","article-title":"Rituximab and obinutuzumab induce direct B-cell death via B-cell receptor (BCR) signaling, but rituximab elicits stronger BCR-derived pro-survival signals diminishing apoptosis","volume":"134","author":"Edelmann","year":"2021","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2144\/000112528","article-title":"Serum albumin leads to false-positive results in the XTT and the MTT assay","volume":"43","author":"Funk","year":"2007","journal-title":"Biotechniques"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2012.02.006","article-title":"Exocytosis of MTT formazan could exacerbate cell injury","volume":"26","author":"L\u00fc","year":"2012","journal-title":"Toxicol Vitro"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tiv.2022.105407","article-title":"An evaluation of a new high-sensitivity PrestoBlue assay for measuring cell viability and drug cytotoxicity using EA.hy926 endothelial cells","volume":"83","author":"Luzak","year":"2022","journal-title":"Toxicol Vitro"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/1087057108329452","article-title":"Comparison of 3 cytotoxicity screening assays and their application to the selection of novel antibacterial hits","volume":"14","author":"Peternel","year":"2009","journal-title":"J Biomol Screen"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.112675","article-title":"Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell Malignancies","volume":"476","author":"Stasi\u0142oj\u0107","year":"2020","journal-title":"J Immunol Methods"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02304-0","article-title":"Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics","volume":"68","author":"Felberg","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.12.3900.012k14_3900_3908","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0277","article-title":"Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains","volume":"104","author":"Bezombes","year":"2004","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2741\/3688","article-title":"Molecular mechanisms of the antitumor effects of anti-CD20 antibodies","volume":"16","author":"Winiarska","year":"2011","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(83)90115-1","article-title":"Use of propidium iodide staining and flow cytometry to measure anti-mediated cytotoxicity: Resolution of complement-sensitive and resistant target cells","volume":"62","author":"Jacobs","year":"1983","journal-title":"J Immunol Methods"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12412","article-title":"Low pH impairs complement-dependent cytotoxicity against IgG-coated target cells","volume":"7","author":"Dantas","year":"2016","journal-title":"Oncotarget"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.9.2771","article-title":"Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species","volume":"98","author":"Bellosillo","year":"2001","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/bs.mie.2019.07.026","article-title":"Flow cytometry-based assessment of direct-targeting anti-cancer antibody immune effector functions","volume":"632","author":"Miller","year":"2020","journal-title":"Methods Enzymol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12026-011-8239-5","article-title":"Membrane attack by complement: The assembly and biology of terminal complement complexes","volume":"51","author":"Tegla","year":"2011","journal-title":"Immunol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1786368\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T05:28:55Z","timestamp":1773293335000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1786368\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2026.1786368"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1786368","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"article-number":"1786368"}}